Results 91 to 100 of about 52,949 (209)
Cancer Medicine, Volume 15, Issue 10, October 2026.ABSTRACT Multiple public databases, including TCGA, GEO, and TARGET, were utilized to comprehensively analyze pyridoxal phosphatase (PDXP) expression profiles across 34 cancer types. We further explored the associations of PDXP expression with clinicopathological features, tumor immune microenvironment, genomic heterogeneity, functional signaling ...
Yingjian Hu +5 more
wiley +1 more source
, 2018 Xiteng Yin,1,2,* Zheng Wei,1,2,* Chuanhui Song,1,2 Chuanchao Tang,1,2 Wenguang Xu,1,2 Yufeng Wang,1,2 Junqi Xie,1,2 Zitong Lin,2,3 Wei Han1,2 1Department of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Medical School of Nanjing ...
Xie JQ +8 more
core
International Journal of Cancer, Volume 159, Issue 7, Page 1715-1734, 1 October 2026.Mutual exclusivity and co‐occurrence of oncogenic mutations reflect functional antagonism or dependence and may inform therapeutic strategies. However, most studies overlook variant‐level patterns. In this comprehensive, cross‐cohort analysis of BRAF, KRAS, and EGFR mutation subtypes, the most significant mutual exclusivity pairs overlapped with ...
Freya Vaeyens +14 more
wiley +1 more source
, 2005 Objective: Interferon-α (IFNα) treatment is associated with up-regulation of epidermal growth factor receptor (HER1/EGFR) expression and marked growth inhibition of colon cancer cell lines in vitro.
Russell, Pamela +4 more
core +1 more source
MedComm, Volume 7, Issue 10, October 2026.The Hippo–YAP/TAZ–TEAD pathway integrates mechanical and biochemical cues to govern organ growth, regeneration, cancer, and fibrosis. This review dissects pathway physiology, TEAD structural pharmacology and ligandable pockets, and therapeutic strategies spanning palmitoylation‐pocket inhibitors, PROTAC degraders, and gene/RNA therapies, highlighting ...
Xiaodan Qu, Zhan‐you Wang
wiley +1 more source
MedCommGefitinib is the most frequently employed anti‐lung cancer drug, but its clinical effectiveness is often compromised due to the development of drug resistance.
Zhouyangfan Peng +3 more
doaj +1 more source
Glutamine Metabolism in Health and Diseases
MedComm, Volume 7, Issue 10, October 2026.Glutamine metabolism acts as a metabolic hub connecting cellular stress adaptation, immune regulation, and disease development. Through regulating energy production, biosynthesis, redox balance, and nitrogen metabolism, glutamine supports cellular homeostasis under physiological and pathological conditions.
Yi Ding +3 more
wiley +1 more source
Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
, 2011 Pietro Carotenuto1, Cristin Roma1, Anna Maria Rachiglio1, Raffaella Pasquale1, Renato Franco2, Giuseppe Antinolfi3, Francovito Piantedosi4, Alfonso Illiano5, Gerardo Botti2, Alessandro Morabito6, Nicola Normanno7, Antonella De Luca71Pharmacogenomic ...
et al +3 more
core
Nano Select, Volume 7, Issue 10, October 2026.Surface‐modified niosomes are introduced as multifunctional nanoparticles for precision tumor treatment that combine hydrophilic and lipophilic drug encapsulation with ligand‐based targeting via antibodies, peptides, transferrin, and folic acid. This modification leads to increased tumor selectivity, facilitates cell entry, and enables enhanced ...
Narges Sahraei +3 more
wiley +1 more source
Table_2_ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC.doc [PDF]
, 2018 Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI), is used clinically as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) with EGFR activating mutations, but the inevitable ...
Lanxiang Wu +11 more
core +1 more source